Target
HDAC2
2 abstracts
Abstract
Presence of somatic/germline homologous recombination repair (HRR) mutations and outcomes in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) receiving first‑line (1L) treatment stratified by BRCA status.Org: Janssen, Janssen Pharmaceuticals, Janssen Research & Development, Janssen-Cilag B.V., Janssen Pharmaceutica NV,
Abstract
Combined inhibition of EZH2 and histone deacetylases as a potential epigenetic therapy for human uterine sarcoma cells.Org: Cancer Biology Department, National Cancer Institute, Vilnius, Lithuania, Cairo University, Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Beijing, China, University of Chicago,